Miltenyi Biomedicine GmbH
Budget
€100 — €0
EP Access
1
accredited persons
Staff
1
0.5 FTE
EU Grants
None
Mission & Goals
Miltenyi Biomedicine is a clinical-stage biopharmaceutical company focused on developing effective cell therapies. Our clinical programs are built on decades of expertise in cell processing, automation, and GMP manufacturing. Our mission is to expand access to cell therapies for patients with difficult-to-treat indications. Our current focus is on hematological cancers, with investigational CAR-T programs in development. Our goal is to increase the number of patients who can benefit from next-generation cell and gene therapies by offering more effective treatment options and reducing time to treatment (for more information explore our pipeline).
EU Legislative Interests
EU Biotechnology Act, revision of EU pharmaceutical legislation, ATMP policy, Research policy, Horizon Europe, Europe’s Beating Cancer Plan, SoHo legislation, EU HTA
Communication Activities
N/A
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Eucope, the European Confederation of Pharmaceutical Entrepreneurs ARM, the Alliance for Regenerative Medicines
Organisation Members
TRANSFORM Alliance (European Alliance for Transformative Therapies): https://www.eucope.org/transform-multi-stakeholder-approach-to-gene-and-cell-therapies/
Additional Information
The estimate is based on 50% of the salary of the Miltenyi Biomedicine employee falling under the scope of the Register, based on the proportion of employee's time spent on these activities, 100% of consultancy costs and of our trade association membership fees
Commissioner Meetings
No recorded meetings with EU commissioners.